XML 34 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Details) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Dec. 31, 2011
Apr. 29, 2009
Noncontrolling Interest [Line Items]            
Amount of CIRM grant award           $ 4,721,706
Cash received from CIRM grant 392,665 392,665 785,330 785,330    
Grants revenue 672,537 442,244 1,074,771 857,855    
Trade accounts receivable 574,000   574,000   353,000  
Grants receivable 120,000   120,000   630,000  
Allowance for doubtful accounts 100,000   100,000   100,000  
Property, Plant and Equipment [Line Items]            
Foreign currency translation loss (182,947) (928,536) (58,859) (1,598,542)    
Foreign currency transaction gain (loss)     5,308 (163,364)    
Income tax penalties and interest accrued 0   0   0  
Warrants [Member]
           
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive shares excluded from computation of diluted loss per share (in shares) 636,613 639,513 636,613 639,513    
Stock Options [Member]
           
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]            
Anti-dilutive shares excluded from computation of diluted loss per share (in shares) 3,433,802 3,130,480 3,433,802 3,130,480    
Equipment [Member] | Minimum [Member]
           
Property, Plant and Equipment [Line Items]            
Equipment useful life     36 months      
Equipment [Member] | Maximum [Member]
           
Property, Plant and Equipment [Line Items]            
Equipment useful life     120 months      
ReCyte Therapeutics, Inc. [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 95.15%   95.15%      
Country     USA      
OncoCyte Corporation [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 75.30%   75.30%      
Country     USA      
OrthoCyte Corporation [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 100.00%   100.00%      
Country     USA      
ES Cell International Pte., Ltd. [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 100.00%   100.00%      
Country     Singapore      
BioTime Asia, Limited [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 81.00%   81.00%      
Country     Hong Kong      
Cell Cure Neurosciences, Ltd. [Member]
           
Noncontrolling Interest [Line Items]            
Grants revenue $ 236,680   $ 246,249      
BioTime ownership (in hundredths) 53.60%   53.60%      
Country     Israel      
LifeMap Sciences, Inc. [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths) 86.30%   86.30%      
Country     USA      
LifeMap Sciences, Ltd. [Member]
           
Noncontrolling Interest [Line Items]            
BioTime ownership (in hundredths)    [1]      [1]      
Country     Israel      
[1] LifeMap Sciences, Ltd. is a wholly-owned subsidiary of LifeMap Sciences, Inc.